The use of kava and cognitive-behavior therapy in the treatment of panic disorder

Cognitive and Behavioral Practice

Volumn 9, Issue 2, 2002, Pages 83-88

  Dattilio, Frank M ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; KAVA; PSYCHOTROPIC AGENT;

ADULT; ANXIETY DISORDER; ARTICLE; BEHAVIOR THERAPY; CASE REPORT; COGNITIVE THERAPY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HERBAL MEDICINE; HUMAN; PANIC; PHOTOSENSITIVITY; PRIORITY JOURNAL; SKIN ALLERGY; VERTIGO; VISUAL IMPAIRMENT;

EID: 0042835691     PISSN: 10777229     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1077-7229(02)80002-5     Document Type: Article

References (44)

1. Almeida, J. C., & Grimsley, E. W. (1996). Coma from the health food store: Interaction between kava and alprazolam. Annals of Internal Medicine 125, 940-941.
2. American Psychiatric Association. (1998). Practice guidelines for the treatment of patients with panic disorder. American Journal of Psychiatry, 155, S1-S34.
3. Astin, J. A. (1998). Why patients use alternative medicine. Results of a national study. Journal of the American Medical Association, 279, 1548-1553.
4. Ballenger, J. C., Burrows, G. D., DuPont, R. L., Lesser, I. M., Noyes, R., Pecknold, J. C., Rifkin, A., & Swinson, R. P. (1988). Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial. An efficacy in short-term treatment. Archives of General Psychiatry, 45, 413-422.
5. Barlow, D. H., Gorman, J. M., Shear, M. K., & Woods, S. W., (2000). Cognitive-behavior therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. Journal of the American Medical Association, 283, 2529-2535.
6. Barlow, D. H., & Lehman, C. L. (1996). Advances in the psychosocial treatment of anxiety disorders. Archives of General Psychiatry, 53, 727-735.
7. Beck, A. T., Steer, R., & Brown, G. (1996). Beck Depression Inventory-II Manual. San Antonio, TX: The Psychological Corporation.
8. Bonn, D., & Bonn, J. (1998). Anxious times for the treatment of anxiety. Lancet, 352, 1126.
9. Chambless, D. L., Caputo, G. C., Bright, P., & Gallagher, R. (1984). Assessment of fear of fear in agoraphobia: The Body Sensations Questionnaire and the Agoraphobic Questionnaire. Journal of Consulting and Clinical Psychology, 52, 1090-1097.
10. Connor, K. M. (1999). Kava Kava: Nature's anxiolytic or "chill pill." ADAA Reporter. X(2), 9-28.
11. Conner, K. M., & Vaughan, D. S. (1999). Kava: Nature's stress relief. New York: Avon.
12. Cottraux, J., Note, I. D., Cungi, C., Legeron, P., Heim, F., Chneiweiss, L., Bernard, G., & Bouvard, M. (1995). A controlled study with cognitive-behavior with buspirone or placebo in panic disorder with agoraphobia. British Journal of Psychiatry, 167, 635-641.
13. Craske, M. G. (1996). Cognitive-behavioral approaches to panic and agoraphobia. In K. S. Dobson & K. D. Craig (Eds.), Advances in cognitive-behavior therapy. Thousand Oaks, CA: Sage.
14. Dattilio, F. M. (1990). Symptom induction and de-escalation in the treatment of panic attacks. Journal of Mental Health Counseling, 12, 515-519.
15. Dattilio, F. M. (1994). SAEB: A method of conceptualization in the treatment of panic. Cognitive and Behavioral Practice, 1, 179-191.
16. Dattilio, F. M., & Salas-Auvert, J. A. (2000). Panic disorder: Assessment and treatment through a wide-angle lens. Phoenix: Zeig, Tucker & Co.
17. Dinardo, P. A., Brown, T. A., & Barlow, D. H. (1995). Anxiety Disorders Interview Schedule for DSM-IV (lifetime version). San Antonio, TX: Psychological Corporation.
18. Dozois, D. J. A., Dobson, K. S., & Ahnberg, J. L. (1998). A psychometric evaluation of the Beck Depression Inventory-II. Psychological Assessment, 10, 83-89.
19. Escher, M., Desmeules, J., Giostra, E., & Mentha, G. (2001). Hepatitis associated with Kava, an herbal remedy for anxiety. British Medical Journal, 322, 139.
20. Flanagan, J., & Jurens, T. (2000). Kava: Piper methysticum. Child and Adolescent Psychopharmacology News, 5(3) 7-10.
21. Hofmann, R., & Winter, U. (1996). Therapeutische Möglichkeiten mit Kava-Kave bei angsterkrankungen. Psycho, 22(Suppl.), 51-53.
22. Jussofie, A., Schmiz, A., & Hiemke, C. (1994). Kavapyrone enriched extract from piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology, 116, 469-474.
23. Kinzler, E. J., Krömer, E., & Lehmann, J. (1991). Wirksamkeit eines spezialextraktes bei patienten mit angst-spannungs und erregungszustöanden nichtpsychotischer Genese. Arzneimttelforsch, 41, 584-588.
24. Klosko, J. S., Barlow, D. H., Tassinari, R. B., & Cerny, J. A. (1990). Comparison of alprozalam and cognitive-behavior therapy in the treatment of panic disorder: A preliminary report. In I. Hand & H. U. Wittchen (Eds.), Panic and phobias 2: Treatment and variables affecting course and outcome. Berlin: Springer-Verlag.
25. Liebowitz, M. R., Fryer, A. B., & Gorman, J. M. (1986). Alprazolam in the treatment of panic disorder. Journal of Clinical Psychopharmacology, 6, 13-20.
26. Marks, I. M., Swinson, R. P., Basoglu, M., Kuch, K., Noshirvani, H., O'Sullivan, G., Lelliot, P. T., Kirby, M., McName, G., Sengun, S., & Wickwire, K. (1993). Alprazolam and exposure alone and combined in panic disorder with agoraphobia: A controlled study in London and Toronto. British Journal of Psychiatry, 162, 776-787.
27. McNally, R. J. (1994). Panic disorder: A critical analysis. New York: Guilford Press.
28. Mischoulon, D., & Rosenbaum, J. F. (1999). The use of natural remedies in psychiatry: A commentary. Harvard Review of Psychiatry, 6, 279-283.
29. Noyes, R., Jr., Anderson, D. J., Clancy, J., Crowe, R. R., Slymen, D. J., Ghoneim, M. M., & Hinnicks, J. E. (1984). Diazepam and propranolol in panic disorder and agoraphobia. Archives of General Psychiatry, 41, 287-292.
30. Otto, M. W., Gould, R. A., & McLean, R. Y. S. (1996) Letter to editor: The effectiveness of cognitive-behavior therapy for panic disorder without concurrent medication treatment: A reply to Power and Sharp. Journal of Psychopharmacology, 10, 254-256.
31. Otto, M. W., Pollack, M. H., & Maki, K. M. (2000). Empirically supported treatments for panic disorder: Costs, benefits and stepped care. Journal of Consulting and Clinical Psychology, 68, 556-563.
32. Pittler, M. H., & Ernst, E. (2000). Efficacy of kava extract for treating anxiety: Systematic review and meta-analysis. Journal of Clinical Psychopharmacology, 20, 84-89.
33. Pollack, M. H., Otto, M. W., Kaspi, S. P., Hammerness, P. G., & Rosenbaum, J. F. (1994). Cognitive-behavior therapy for treatment-refractory panic disorder. Journal of Clinical Psychiatry, 55, 200-205.
34. Priest, R. G., & Montgomery, S. A. (1988). Benzodiazepines and dependence: A college statement. Bulletin Review of College Psychiatry, 12, 107-108.
35. Rachman, S. (1990). Fear and courage (2nd ed.). New York: Freeman.
36. Schelosky, L., Raffauf, C., Jendroska, K., & Poewe, W. (1995). Kava and dopamine antagonism. The Journal of Neurology, Neurosurgery and Psychiatry, 58, 639-640.
37. Schultz, V., Hänsel, R., & Tyler, V. E. (1998). Rational phytotherapy: A physician's guide to herbal medicine (3rd ed.). Berlin: Springer.
38. Sheehan, D. V., Ballenger, J., & Jacobson, G. (1980). Treatment of endogeneous anxiety with phobic, hysterical and hypochondriacal symptoms. Archives of General Psychiatry, 37, 51-59.
39. Siegers, C. P., Harold, E., Krall, B., Meng, G., & Habs, M. (1992). Ergebnisse einer anwendungsbeobachtung L1090 mit Laitan® Kapseln. Arztl Forsch, 39, 7-11.
40. Singh, N. N., Ellis, C. R., & Sing, N. N. (1998, April). A double-blind placebo-controlled study of the effects of Kava (Kavatrol TM) on daily stress and anxiety on adults. Paper presented at the 3rd Annual Alternative Symposium, San Diego.
41. Singh, Y. N. (1992). Kava: An overview. Journal of Ethnopharmacology, 37, 13-45.
42. Speigel, D. A., Bruce, T. J., Gregg, S. F., & Nuzzarello, A. (1994). Does cognitive therapy assist slow-taper alprazolam discontinuation in panic disorders? American Journal of Psychiatry, 151, 867-881.
43. Volz, H. P., & Kieser, M. (1997). Kava-Kava extract WS 1490 versus placebo in anxiety disorder: A randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry, 30, 1-5.
44. Woelk, H. (1993). Behandlung von angst-patienten. Kava-spezialex-trakt WS 1490 bei angst-patienten im vergleich zu den benzodiazepinen oxazepam und bromazepam - eine doppelblindstudie in ärztlichen praxen. ZtschrAllgemeinmed, 69, 271-277.